Research Article

Increased Risk of Central Serous Chorioretinopathy among Patients with Nonorganic Sleep Disturbance

Peng-Tai Tien,1,2 Chien-Yu Lai,3 Chun-Ju Lin,2,4 Wen-Lu Chen,1,2 Po-Kang Lin,5,6 Chih-Hsin Muo,7,8 Yi-Yu Tsai,1,2,4 Lei Wan,9,10 Wen-Chao Ho,11 and Hui-Ju Lin2

1Graduate Institute of Clinical Medical Science, College of Medicine, China Medical University, Taichung, Taiwan
2Department of Ophthalmology, China Medical University Hospital, Taichung, Taiwan
3School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan
4School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan
5School of Medicine, National Yang-Ming University, Taipei, Taiwan
6Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan
7Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan
8College of Medicine, China Medical University, Taichung, Taiwan
9Department of Biotechnology, Asia University, Taichung, Taiwan
10Department of Obstetrics and Gynecology, China Medical University Hospital, Taichung, Taiwan
11Department of Public Health, College of Public Health, China Medical University, Taichung, Taiwan

Correspondence should be addressed to Lei Wan; leiwan1973@gmail.com, Wen-Chao Ho; whocmu@gmail.com, and Hui-Ju Lin; d2396@mail.cmuh.org.tw

Received 24 September 2019; Revised 6 January 2020; Accepted 18 January 2020; Published 12 February 2020

Academic Editor: Ciro Costagliola

Copyright © 2020 Peng-Tai Tien et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. Patients with central serous chorioretinopathy (CSC) typically present with acute visual impairment and metamorphopsia. The disease previously has been associated with psychological stress. Population-based cohort studies on the risk of CSC among patients with nonorganic sleep disturbance (NOSD) are limited. An early sign of psychiatric disorder was probably sleep disturbance. Furthermore, psychological stress may be caused by sleep disturbance. We investigated the relationship between NOSD and the incidence of CSC. Design. Longitudinal cohort study. Participants. We used the Longitudinal Health Insurance Database and collected the data of 53,743 NOSD patients without CSC between 2000 and 2005 as the study group. Four-fold controls were selected randomly from those without neither sleep disturbance nor a CSC history with frequency matching of age, sex, and index-year. Methods. The difference in sex, age group, comorbidities, and steroid use between the two groups was analyzed by the \( \chi^2 \) test. Cox-proportional hazard regression was utilized to estimate the hazard ratio (HR) and 95% confidence intervals (95% CI) for comparison of the two groups. Kaplan–Meier analysis was applied to measure the cumulative incidence of CSC. Furthermore, the log-rank test was used to test the incidence difference between the two groups. Main Outcome Measures. The incidence rate of CSC in the following years until 2011 was detected. Results. During a mean follow-up of 7.36 ± 2.88 years, NOSD patients had a higher incidence of CSC than the controls (3.10 vs. 1.86 per 10,000 person-years; adjusted HR, 1.65; 95% CI, 1.34–2.02). Men had a higher risk of CSC than women. Sensitivity analyses stratified by sex, age group, or comorbidity condition showed consistently that NOSD patients had a higher risk of CSC than their controls. Dose-response showed that higher NOSD severity had even higher CSC risk. Conclusions. NOSD is an independent indicator for the increased risk of subsequent CSC development.
1. Introduction

Central serous chorioretinopathy (CSC) is a maculopathy typically presenting with relative central scotoma, metamorphopsia, and decreased central vision; it mainly affects middle-aged men [1, 2]. CSC is one of the most common nonsurgical retinopathies [2]. The typical finding of CSC is serous neurosensory retinal detachment over the posterior pole due to impaired activity of the retinal pigment epithelium and changes of choroidal hemodynamics [3, 4]. CSC is frequently self-limited with good recovering visual outcome [5]. However, CSC recurrence may result in irreversible visual acuity loss due to extensive retinal pigment epithelium damage [6].

The etiology of CSC remains unclear. The disease has been associated with psychological stress [7–9]. Studies also have revealed that endogenous hypercortisolism, psychopharmacologic medication, glucocorticoid medication, hypertension, elevated circulating cortisol and catecholamines, and peptic ulcer are risk factors for CSC [10–16]. Sleep disturbance is a common complaint and source of distress in community surveys of self-reported health problems [17–19]. An early sign of psychiatric disorder was probably sleep disturbance. Furthermore, psychological stress may be caused by sleep disturbance [20]. Leveque et al. [21] found CSC patients may be more likely than others to have sleep apnea. Kloos et al. [22] reported that sleep apnea may be a risk factor for the development of CSC. Bouquet et al. [8], Liu et al. [15], and Eom et al. [23] also reported that sleep disturbance was associated with CSC. Nevertheless, some studies revealed that patients with CSC were not statistically significant related to those with sleep apnea [24, 25]. The controversial results indicated that more and detailed studies are required to understand the association between sleep disturbance with CSC [15]. Since sleep apnea is generally with organic origin, in the present study, we intended to understand whether sleep disturbance with nonorganic origin exhibits higher risk of CSC. We analyzed and compared the incidences of CSC in the NOSD group and in the control group without NOSD using the national population-based dataset from Taiwan National Health Insurance (TNHI).

2. Methods

2.1. Database. The Taiwan Bureau of National Health Insurance (TBNHI) integrated all 13 public health insurance systems since 1995 into a large insurance program. Enrollment in this program is mandatory for people in Taiwan, and the covered rate is over 99% Taiwanese. TBNHI entrusted National Health Research Institutes to construct and maintain the National Health Insurance Research Database (NHIRD) from this program. The Longitudinal Health Insurance Database (LHID) was a part of NHIRDs, and it contained one million beneficiaries selected randomly from the year 2000 Registry of Beneficiaries. This database included all inpatient and outpatient medical claims for each beneficiary from the start of 1996 to the end of 2011. The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) was used to identify the disease. The patient’s identification code in the NHIRDs was recorded by TBNHI based on the Personal Information Protection Act. All researchers signed the written agreement for no intention of attempting to obtain patients’ privacy. This study was also approved by the Research Ethics Committee in China Medical University Hospital, Taiwan.

2.2. Study Population, Outcome, and Comorbidity. We collected 53,862 patients with NOSD diagnosis (ICD-9-CM 307.4 and 780.5) and age at 20–50 years between 2000 and 2005 from LHID as the NOSD cohort. The date for NOSD diagnosis was defined as the index date. In the NOSD group, NOSD patients with CSC (ICD-9-CM 362.41) were excluded before the index date (n = 119). Controls were selected randomly from people in the LHID without sleep disturbance and CSC history as the control group, with frequency-matched criteria including age (5-year stratum), sex, and index-year at a ratio of 4:1.

All study subjects were followed from the index date to the date when CSC developed. All selected study subjects were followed to the date of withdrawal from this program or the end of 2011. The follow-up time, in person-years, was counted for each study subject. Potential comorbidity we considered included hypertension (ICD-9-CM 401–405), hyperlipidemia (ICD-9-CM 272), diabetes (ICD-9-CM 250), depression (ICD-9-CM 296.2, 296.3, 300.1, and 311), anxiety (ICD-9-CM 300.0, 300.2, 300.3, 308.3, and 309.81), alcohol-related disease (ICD-9-CM 291, 303, 305, 571.0, 571.1, 571.2, 571.3, 790.3, A215, and V11.3), smoking-related disease (ICD-9-CM 305.1, 430–438, 410–414, and 490–496), and obesity (ICD-9-CM). All comorbidities were defined before the index date. Patients who had received steroid treatment within 1 year before CSC development were defined as steroid users.

2.3. Statistical Analysis. The difference between the two groups, demographics, and comorbidity was compared by the χ²-test. The CSC incidences were measured in the NOSD and control groups. The hazard ratio (HR) and 95% confidence intervals (CIs) for CSC and CSC-associated risk factors were estimated in crude and adjusted Cox proportional hazard regression models. An adjusted model controlled for the variables that had significant differences in the crude model. Age-, sex-, comorbidity-, and steroid use-specific risks for CSC in the NOSD group were compared with those in the control group with the Cox model. Furthermore, we estimated the association between CSC and the severity of NOSD. The severity was classified as mild and serious according to NOSD patients who received sleeping pill treatment within 1 year before the CSC occurred. Kaplan–Meier analysis was used to measure the cumulative incidence for CSC during the study period in both groups, and the log-rank test was used to test the difference in incidences between both groups. SAS 9.4 statistical software (SAS Institute, Inc., Cary, NC, USA) was used for all statistical analyses in this study. The significant level was set at P < 0.05, 2-tailed test.
3. Results

We all collected 268,715 study subjects in this retrospective cohort study, 53,743 NOSD patients and 214,972 controls. In the NOSD group, there were more women than men (64.7% vs. 35.3%). The mean age was 36.8 ± 8.40 years. Compared with the controls, NOSD patients were more likely to have comorbidities, including hypertension (10.3% vs. 5.59%; 95%, \(P < 0.0001\)), diabetes (3.48% vs. 2.33%; 95%, \(P < 0.0001\)), hyperlipidemia (8.82% vs. 4.96%; 95%, \(P < 0.0001\)), depression (5.60% vs. 1.09%; 95%, \(P < 0.0001\)), anxiety (10.9% vs. 2.44%; 95%, \(P < 0.0001\)), alcohol-related disease (2.93% vs. 1.12%; 95%, \(P < 0.0001\)), smoking-related disease (25.4% vs. 13.9%; 95%, \(P < 0.0001\)), and obesity (1.22% vs. 0.77%; 95%, \(P < 0.0001\)). NOSD patients received steroid treatment more often than the control group (37.2% vs. 26.8%; 95%, \(P < 0.0001\); Table 1).

During a mean 7.36 ± 2.88 years of follow-up, 281 and 144 patients had CSC in the control and NOSD groups, respectively, with incidences of 1.86 and 3.10 per 10,000 person-years, respectively (Table 2). After 12 years of follow-up, the cumulative incidence for CSC in the NOSD cohort was approximately 0.09% higher than the control cohort (0.29% vs. 0.20%, log rank test \(P < 0.0001\); Figure 1).

NOSD patients had a 1.71-and 1.65-fold risk for CSC compared with non-NOSD controls in the crude and adjusted Cox models (95% CI, 1.40–2.09 and 1.34–2.02, respectively). In the multivariable Cox model, men and steroid usage had a higher risk for CSC than women and nonsteroid usage (HR, 2.51 and 1.33; 95% CI, 2.07–3.05 and 1.08–1.63, respectively; Table 2).

Table 3 presents the risk for CSC in the NOSD compared with the non-NOSD control group stratified by age, sex, comorbidity, and steroid use. NOSD women had a 1.72-fold higher risk than control women, and NOSD men also had a 1.59-fold higher risk than control men in the multivariable Cox model. No matter at what age, NOSD patients had a significantly more than 1.44-fold risk for CSC than controls. NOSD patients with or without any other comorbidity also had a higher risk of CSC. Furthermore, NOSD patients without steroid treatment had a significantly higher risk of developing CSC.

The association between CSC and NOSD severity is shown in Table 4. Of the NOSD patients, 61% (32,839/53,743) received sleeping pill treatment and were classified into the serious NOSD group. The CSC incidence increased with NOSD severity from 1.86 to 3.01 and 3.16 per 10,000 person-years in the controls, mild-NOSD, and serious-NOSD groups, respectively (\(P\) for trend < 0.0001). Compared with the control group, serious-NOSD patients exhibited 1.72-fold (95% CI, 1.35–2.20) increased risk of having CSC and a 1.55-fold risk (95% CI, 1.16–2.07) in the mild-NOSD patients.

4. Discussion

To our knowledge, this study is the first to assess the relationship of NOSD inducing CSC, with a large-scale nationwide representative database (\(n = 268,715\)) and long-term follow-up study design. NOSD patients had a higher risk for CSC, no matter in which sex, age group, or comorbidity condition.

NOSD patients had higher alcohol-related and smoking-related diseases. However, alcohol and smoking were not significant risk factors for CSC in our study. A recent study also had shown that tobacco was not involved in the development of CSC [15]. NOSD was related to CSC, independent of alcohol-related and smoking-related diseases. The severity of NOSD was defined by the use of sleeping pills. We found a higher incidence of CSC in patients with serious NOSD than mild NOSD patients, which suggested the importance of NOSD in the pathogenesis of CSC. The data also suggested that taking sleeping pills may increase the incidence of CSC. We did not analyze the effect of each different sleeping pills on the incidence of CSC in this study. We are now evaluating the outcomes of each different sleeping pills on the incidence of CSC.

It has been noted that corticosteroids were associated with the initiation, exacerbation or prolongation of central serous chorioretinopathy [11]. Another report indicated that not only the systematic but also inhalant or nasal use of steroid could increase the risk of CSC [15]. Nevertheless, NOSD patients had a higher CSC risk regardless of steroid use in our study, especially among those who did not undergo steroid treatment showing significant difference. In this study, we did not discuss the dosage and duration of the steroids, which may cause the discrepancy between our results and the reported data.

The significant points of our study are that the source of patients is based on a nationwide population-based database, which covers over 99% of the population in Taiwan and decreases the selection bias. Moreover, the longitudinal study was used to assess CSC risk-related NOSD.

This study has some potential limitations. First, diagnoses of CSC from health insurance database have been often challenged. However, the best effort had been made in this large population study based on NHIRD as in many reports in the literature [16, 25–28]. Second, personal information, such as psychological stress, alcohol/cigarette consumption, and body mass index (BMI), was not available from the administrative database, and this somehow may have compromised our results. However, after considering alcohol- and smoking-related diseases, the results in our study were not significant. Bordie et al. [24] proposed that BMI might bias the relationship between sleep apnea and CSC. Thus, we considered obesity as another comorbidity, and the result in our study was also not significant. Third, several asymptomatic or mildly symptomatic CSC patients may not have visited an ophthalmologic clinic, which may have led to underestimation of the risk with nondifferential misclassification. Moreover, there is not standardized diagnosis tool available on NOSD for each different physician. Some patients may actually suffer from different sleep disorders.

In our multivariable Cox model, men had a higher risk for CSC than women (HR, 2.51; 95% CI, 2.07–3.05; Table 2). This is consistent with a previous study showing CSC to be a male-predominant disease [1, 2, 26]. Sleep disturbance is a
Table 1: Demographic characteristics between NOSD and comparison cohort.

| Characteristics   | NOSD N = 53743 (n) | %    | Comparisons N = 214972 (n) | %    | P value
|-------------------|---------------------|------|----------------------------|------|---------|
| Sex               |                     |      |                            |      | 0.99    |
| Women             | 34,774              | 64.7 | 139,096                    | 64.7 |         |
| Men               | 18,969              | 35.3 | 75,876                     | 35.3 |         |
| Age (years)       |                     |      |                            |      | 0.99    |
| 20–29             | 12,479              | 23.2 | 49,916                     | 23.2 |         |
| 30–39             | 18,627              | 34.7 | 74,508                     | 34.7 |         |
| 40–50             | 22,637              | 42.1 | 90,548                     | 42.1 |         |
| Mean              | 36.8                | 8.40 | 37.1                       | 8.25 |         |
| Comorbidity       |                     |      |                            |      |         |
| Hypertension      | 5548                | 10.3 | 12,026                     | 5.59 | <0.0001 |
| Diabetes          | 1870                | 3.48 | 5000                       | 2.33 | <0.0001 |
| Hyperlipidemia    | 4742                | 8.82 | 10,658                     | 4.96 | <0.0001 |
| Depression        | 3010                | 5.60 | 2353                       | 1.09 | <0.0001 |
| Anxiety           | 5876                | 10.9 | 5249                       | 2.44 | <0.0001 |
| Alcohol-related disease | 1577 | 2.93 | 2407                       | 1.12 | <0.0001 |
| Smoking-related disease | 13,645 | 25.4 | 29,896                     | 13.9 | <0.0001 |
| Obesity           | 654                 | 1.22 | 1646                       | 0.77 | <0.0001 |
| Steroid usage     | 19,964              | 37.2 | 57,563                     | 26.8 | <0.0001 |

*Chi-square test. NOSD: nonorganic sleep disturbance.

Table 2: Incidence and risk for CSC and associated comorbidities.

| Event no. | Person per years | Rate § | Crude HR § (95% CI) | Adjusted HR § (95% CI) |
|-----------|------------------|--------|---------------------|------------------------|
| NOSD No   | 281              | 1,512,968 | 1.86               | 1.00                   |
| Yes       | 144              | 464,176  | 3.10 (1.71–2.09)   | 1.65 (1.34–2.02)       |
| Sex Women | 176              | 1,256,555 | 1.40               | 1.00                   |
| Men       | 249              | 720,590  | 3.46 (2.47–3.00)   | 2.51 (2.07–3.05)       |
| Age (years) |                 |         |                     |                        |
| 20–29     | 86               | 461,051  | 1.87               | 1.00                   |
| 30–39     | 155              | 689,607  | 2.25               | 1.21 (0.93–1.58)       |
| 40–50     | 184              | 826,487  | 2.23               | 1.20 (0.93–1.55)       |
| Comorbidity |               |         |                     |                        |
| Hypertension |             |         |                     |                        |
| No        | 38               | 1,849,898 | 2.09               | 1.00                   |
| Yes       | 38               | 127,246  | 2.99 (1.44 (1.03–2.01) | 1.08 (0.76–1.54)      |
| Diabetes  | 410              | 1,928,583 | 2.13               | 1.00                   |
| Yes       | 15               | 48,562   | 3.09               | 1.45 (0.87–2.43)       |
| Hyperlipidemia |          |         |                     |                        |
| No        | 386              | 1,866,904 | 2.07               | 1.00                   |
| Yes       | 39               | 110,241  | 3.54               | 1.72 (1.24–2.39)       | 1.34 (0.94–1.90)      |
| Depression |               |         |                     |                        |
| No        | 414              | 1,938,883 | 2.14               | 1.00                   |
| Yes       | 11               | 38,262   | 2.87               | 1.35 (0.74–2.46)       |
| Anxiety   | 401              | 1,897,576 | 2.11               | 1.00                   |
| Yes       | 24               | 79,568   | 3.02               | 1.43 (0.95–2.16)       |
| Alcohol-related disease | 416 | 1,950,593 | 2.13               | 1.00                   |
| Yes       | 9                | 26,552   | 3.39               | 1.57 (0.81–3.04)       |
| Smoking-related disease | 349 | 1,664,185 | 2.10               | 1.00                   |
| Yes       | 76               | 312,959  | 2.43               | 1.16 (0.91–1.49)       |
| Obesity   | 421              | 1961556  | 2.15               | 1.00                   |
| Yes       | 4                | 15589    | 2.57               | 1.18 (0.44–3.15)       |
| Steroid usage |          |         |                     |                        |
| No        | 279              | 1,420,146 | 1.96               | 1.00                   |
| Yes       | 146              | 556,999  | 2.62               | 1.34 (1.09–1.63)       | 1.33 (1.08–1.63)** |

§ Per 10,000 person-years. *P < 0.05, **P < 0.01, ***P < 0.001. CSC: central serous chorioretinopathy, NOSD: nonorganic sleep disturbance, HR: hazard ratio, CI: confidence interval.
common health issue. Many sleep disorders, such as insomnia, hypersomnia, and sleep apnea, are included in sleep disturbance. Inadequate sleep is associated with cardiovascular disease [29]. CSC also was noted to be associated with an increased risk of stroke and coronary heart disease [27, 28]. Elevated catecholamine and cortisol levels were found in a sleep apnea population [30, 31]. Altered catecholamine levels and sympathetic activity often have been reported to accompany sleep disturbance [31, 32]. Sun et al. found that plasma concentrations of both catecholamines (epinephrine and norepinephrine) were significantly higher in active CSC than normal subjects, and then decreased to normal in the convalescent stage. They also found that plasma concentration of epinephrine was

Figure 1: Cumulative incidence for central serous chorioretinopathy (CSC) in the no organic sleep disturbance (NOSD) and control cohorts. After 12 years of follow-up, the cumulative incidence for CSC in the NOSD cohort was approximately 0.09% higher than that in the control cohort (0.29% vs. 0.20%, log-rank test ($P < 0.0001$)).

Table 3: Incidence and risk for CSC in NOSD compared with non-NOSD cohort stratified by age, sex, comorbidity, and steroid usage.

| Sex       | NOSD event no. | Person per years | Rate $^a$ | Control event no. | Person per years | Rate $^a$ | HR 95% (CI) | Adjusted  |
|-----------|----------------|------------------|-----------|-------------------|------------------|-----------|-------------|-----------|
| Women     | 64             | 303,885          | 2.11      | 112               | 952,670          | 1.18      | 1.82 (1.34–2.48)** | 1.72 (1.26–2.35)** |
| Men       | 80             | 160,291          | 4.99      | 169               | 560,300          | 3.02      | 1.69 (1.29–2.20)** | 1.59 (1.21–2.09)** |
| Age (years)$^b$ |            |                  |           |                   |                  |           |             |           |
| 20–29     | 34             | 105,361          | 3.23      | 52                | 355,690          | 1.46      | 2.24 (1.46–3.46)** | 2.26 (1.46–3.50)** |
| 30–39     | 52             | 161,231          | 3.23      | 103               | 528,375          | 1.95      | 1.69 (1.21–2.37)** | 1.62 (1.15–2.27)** |
| 40–50     | 58             | 197,584          | 2.94      | 126               | 628,903          | 2.00      | 1.50 (1.10–2.05)$^*$ | 1.44 (1.05–1.98)$^*$ |
| Comorbidity$^c$ |        |                  |           |                   |                  |           |             |           |
| Without any one | 68         | 254048           | 2.68      | 214               | 1190351          | 1.80      | 1.52 (1.15–1.99)** | 1.52 (1.15–2.00)** |
| With any one | 76          | 210128           | 3.62      | 67                | 322617           | 2.08      | 1.79 (1.28–2.48)** | 1.76 (1.26–2.44)** |
| Steroid usage$^d$ |    |                  |           |                   |                  |           |             |           |
| No        | 92             | 292,090          | 3.15      | 187               | 1,128,056        | 1.66      | 1.94 (1.51–2.49)** | 1.90 (1.48–2.45)** |
| Yes       | 52             | 172,087          | 3.02      | 94                | 384,912          | 2.44      | 1.26 (0.90–1.77) | 1.28 (0.91–1.80) |

$^a$Adjusted for hyperlipidemia, hypertension, and steroid use. $^b$Adjusted for sex, hyperlipidemia, hypertension, and steroid use. $^c$Adjusted for sex and steroid use. $^d$Adjusted for sex, hyperlipidemia, and hypertension. $^*$Per 10000 person-years. $^P < 0.05, **P < 0.01, ***P < 0.001. CSC: central serous chorioretinopathy, NOSD: nonorganic sleep disturbance, HR: hazard ratio, CI: confidence interval.
significantly correlated with macular edema. They proposed that prolonged stimulation of high catecholamine level might provoke focal RPE cells dysfunction, resulting in a breakdown of the outer blood-retinal barrier and then diffusion of fluids, which promoted CSC [33]. Those pathophysiological pathways might constitute a hypothetical connection between NOSD and CSC.

In conclusion, we demonstrated large-scale epidemiological evidence of a significantly increased risk for subsequent CSC development among an NOSD population. Decreased central vision or metamorphopsia in NOSD patients may need further macular examinations to exclude the possibility of CSC.

Abbreviations

CSC: Central serous chorioretinopathy  
NOSD: Nonorganic sleep disturbance  
HR: Hazard ratio  
CI: Confidence intervals  
TNHI: Taiwan National Health Insurance  
TBNHI: Taiwan Bureau of National Health Insurance  
NHIRD: National Health Insurance Research Database  
LHID: Longitudinal Health Insurance Database  
ICD-9-CM: International Classification of Diseases, Ninth Revision, Clinical Modification.

Data Availability

The data used to support the findings of this study are included within the article.

Disclosure

Nonorganic sleep disturbance is an independent indicator for the increased risk of subsequent central serous chorioretinopathy development. Early treatment of nonorganic sleep disturbance potentially can prevent the onset of central serous chorioretinopathy.

Conflicts of Interest

The authors declare no conflicts of interest.

Acknowledgments

This work was supported in part by the Ministry of Science and Technology, Taiwan, Republic of China (MOST105-2628-B-039-008-MY3 and MOST107-2320-B-039-049-MY3), the Ministry of Health and Welfare, Taiwan (MOHW109-TDU-B-212-114004), China Medical University Hospital (DMR-106-178), China Medical University (CMU108-ASIA-05), MOST Clinical Trial Consortium for Stroke (MOST 108-2321-B-039-003-), and Tseng-Lien Lin Foundation, Taichung, Taiwan.

References

[1] A. S. Kitzmann, J. S. Pulido, N. N. Diehl, D. O. Hodge, and J. P. Burke, "The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002," Ophthalmology, vol. 115, no. 1, pp. 169–173, 2008.
[2] M. Wang, J. C. Munch, P. W. Hasler, C. Prünte, and M. Larsen, "Central serous chorioretinopathy," Acta Ophthalmologica, vol. 86, no. 2, pp. 126–145, 2008.
[3] N. Kitaya, T. Nagaoka, T. Hikichi et al., "Features of abnormal choroidal circulation in central serous chorioretinopathy," British Journal of Ophthalmology, vol. 87, no. 6, pp. 709–712, 2003.
[4] D. R. Guyer, L. A. Yannuzzi, and J. S. Slakter, "Digital indocyanine green videoangiography of central serous chorioretinopathy," Archives of Ophthalmology, vol. 112, no. 8, pp. 1057–1062, 1994.
[5] M. Gemenetzi, G. De Salvo, and A. J. Lotery, "Central serous chorioretinopathy: an update on pathogenesis and treatment," Eye, vol. 24, no. 12, pp. 1743–1756, 2010.
[6] R. H. Loo, I. U. Scott, H. W. Flynn et al., "Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy," Retina, vol. 22, no. 1, pp. 19–24, 2002.
[7] A. Sahin, Y. Bez, M. C. Kaya, F. M. Türkcü, M. Sahin, and H. Yüksel, "Psychological distress and poor quality of life in patients with central serous chorioretinopathy," Seminars in Ophthalmology, vol. 29, no. 2, pp. 73–76, 2014.
[8] E. Bousquet, M. Dhundass, M. Lehmann et al., "Shift work: a risk factor for central serous chorioretinopathy," American Journal of Ophthalmology, vol. 165, pp. 23–28, 2016.
[9] Y.-K. Kim, S. J. Woo, K. H. Park, Y. K. Chi, J. W. Han, and K. W. Kim, "Association of central serous chorioretinopathy with psychosocial factors is dependent on its phase and subtype," Korean Journal of Ophthalmology, vol. 32, no. 4, pp. 281–289, 2018.
[10] E. A. Bouzas, M. H. Scott, G. Mastorakos, G. P. Chrousos, and M. J. Kaiser-Kupfer, "Central serous chorioretinopathy in endogenous hypercortisolism," Archives of Ophthalmology, vol. 111, no. 9, pp. 1229–1233, 1993.
[11] M. K. Tittl, R. F. Spaide, D. Wong et al., "Systemic findings associated with central serous chorioretinopathy," American Journal of Ophthalmology, vol. 128, no. 1, pp. 63–68, 1999.
[12] R. Haimovici, S. Koh, D. R. Gagnon, T. Lehrfeld, and S. Wellik, "Risk factors for central serous chorioretinopathy," Ophthalmology, vol. 111, no. 2, pp. 244–249, 2004.
[13] S. P. Garg, T. Dada, D. Talwar, and N. R. Biswas, “Endogenous cortisol profile in patients with central serous chorioretinopathy,” *British Journal of Ophthalmology*, vol. 81, no. 11, pp. 962–964, 1997.

[14] J. Sun, J. Tan, Z. Wang, H. Yang, X. Zhu, and L. Li, “Effect of catecholamine on central serous chorioretinopathy,” *Journal of Huazhong University of Science and Technology (Medical Sciences)*, vol. 23, no. 3, pp. 313–316, 2003.

[15] B. Liu, T. Deng, and J. Zhang, “Risk factors for central serous chorioretinopathy,” *Retina*, vol. 36, no. 1, pp. 9–19, 2016.

[16] S.-N. Chen, I. Lian, Y.-C. Chen, and J.-D. Ho, “Increased incidence of peptic ulcer disease in central serous chorioretinopathy patients,” *Retina*, vol. 35, no. 2, pp. 231–237, 2015.

[17] I. Karacan, J. I. Thornby, M. Anch et al., “Prevalence of sleep disturbance in a primarily urban Florida County,” *Social Science & Medicine (1967)*, vol. 10, no. 5, pp. 239–244, 1976.

[18] E. O. Bixler, A. Kales, C. R. Soldatos, J. D. Kales, and S. Healey, “Prevalence of sleep disorders in the Los Angeles metropolitan area,” *American Journal of Psychiatry*, vol. 136, no. 11, pp. 1479–1484, 1979.

[19] G. D. Mellinger, M. B. Balter, and E. H. Uhlenhuth, “Insomnia and its treatment,” *Archives of General Psychiatry*, vol. 42, no. 3, pp. 225–232, 1985.

[20] D. E. Ford and D. B. Kamerow, “Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention?” *JAMA: The Journal of the American Medical Association*, vol. 262, no. 11, pp. 1479–1484, 1989.

[21] T. K. Leveque, L. Yu, D. C. Musch, R. D. Chervin, and D. N. Zacks, “Central serous chorioretinopathy and risk for obstructive sleep apnea,” *Sleep and Breathing*, vol. 11, no. 4, pp. 253–257, 2007.

[22] P. Kloos, I. Laube, and A. Thoelen, “Obstructive sleep apnea in patients with central serous chorioretinopathy,” *Graef’s Archive for Clinical and Experimental Ophthalmology*, vol. 246, no. 9, pp. 1225–1228, 2008.

[23] Y. Eom, J. Oh, S.-W. Kim, and K. Huh, “Systemic factors associated with central serous chorioretinopathy in Koreans,” *Korean Journal of Ophthalmology*, vol. 26, no. 4, pp. 260–264, 2012.

[24] F. L. Brodie, E. S. Charlson, T. S. Aleman et al., “Obstructive sleep apnea and central serous chorioretinopathy,” *Retina*, vol. 35, no. 2, pp. 238–243, 2015.

[25] D.-C. Tsai, S.-J. Chen, and C.-C. Huang, “Epidemiology of idiopathic central serous chorioretinopathy in Taiwan, 2001–2006: a population-based study,” *PLoS One*, vol. 8, no. 6, Article ID e66858, 2013.

[26] D.-C. Tsai, S.-J. Chen, C.-C. Huang et al., “Risk of central serous chorioretinopathy in adults prescribed oral corticosteroids,” *Retina*, vol. 34, no. 9, pp. 1867–1874, 2014.

[27] D.-C. Tsai, C.-C. Huang, S.-J. Chen et al., “Central serous chorioretinopathy and risk of ischaemic stroke: a population-based cohort study,” *British Journal of Ophthalmology*, vol. 96, no. 12, pp. 1484–1488, 2012.

[28] S.-N. Chen, Y.-C. Chen, and I. Lian, “Increased risk of coronary heart disease in male patients with central serous chorioretinopathy: results of a population-based cohort study,” *British Journal of Ophthalmology*, vol. 98, no. 1, pp. 110–114, 2014.

[29] M. Partinen, P. T. Putkonen, J. Kapiro, M. Koskenvuo, and I. Hilakivi, “Sleep disorders in relation to coronary heart disease,” *Acta Medica Scandinavica Supplementum*, vol. 211, no. 5660, pp. 69–83, 1982.

[30] D. E. Henley, G. M. Russell, J. A. Douthwaite et al., “Hypothalamic–pituitary–adrenal axis activation in obstructive sleep apnea: the effect of continuous positive airway pressure therapy,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 94, no. 11, pp. 4234–4242, 2009.

[31] N. McArdle, D. Hillman, L. Bellin, and G. Watts, “Metabolic risk factors for vascular disease in obstructive sleep apnea,” *American Journal of Respiratory and Critical Care Medicine*, vol. 175, no. 2, pp. 190–195, 2007.

[32] P. E. Peppard, T. Young, M. Palta, and J. Skatrud, “Prospective study of the association between sleep-disordered breathing and hypertension,” *New England Journal of Medicine*, vol. 342, no. 19, pp. 1378–1384, 2000.

[33] J. H. Sun, J. Tan, Z. Wang, H. Yang, X. Zhu, and L. Li, “Effect of catecholamine on central serous chorioretinopathy,” *Journal of Huazhong University of Science and Technology-Medical Sciences*, vol. 23, no. 3, pp. 313–316, 2003.